The role of sentinel-node biopsy in ovarian cancer.

IF 1 Q2 Medicine Minerva ginecologica Pub Date : 2020-12-01 Epub Date: 2020-11-03 DOI:10.23736/S0026-4784.20.04691-2
Pawel Mach, Rainer Kimmig, Paul Buderath
{"title":"The role of sentinel-node biopsy in ovarian cancer.","authors":"Pawel Mach,&nbsp;Rainer Kimmig,&nbsp;Paul Buderath","doi":"10.23736/S0026-4784.20.04691-2","DOIUrl":null,"url":null,"abstract":"<p><p>Lymph node involvement is an important prognostic factor in early and advanced epithelial ovarian cancer (EOC). However, to date there is no reliable method of detecting lymph node involvement, apart from surgical staging. Thus, pelvic and paraaortic lymphadenectomy (LNE) are still part of standard surgery of early ovarian cancer. There is conflicting evidence about the therapeutic value of systematic LNE in early EOC. Thus, the developmemt of a method to predict nodal status accurately, without extensive LNE, is the subject of ongoing research. Sentinel lymphadenectomy (SLN) has become a standard procedure in oncological surgery. However, SLN is not yet an established and widely accepted procedure for EOC. This review aimed at summarizing available evidence on its feasibility and reliability in EOC. Overall, evidence of SLN in early EOC is still scarce. So far, only small series of patients with a variety of tracers and injection sites were published. From the available literature, the most promising technique seems to be injection into the infundibulopelvic, as well as the proper ovarian ligament. Indocyanine green seems to be an excellent tracer for successful SLN of ovarian tumors, which can be used during laparoscopic or robotic surgery. The detection rates and true positive rates of studies support further investigation of the technique. Results from prospective studies, e.g. the ongoing SELLY trial, are necesssary to implement SLN into the standard treatment of early EOC.</p>","PeriodicalId":18745,"journal":{"name":"Minerva ginecologica","volume":"72 6","pages":"399-403"},"PeriodicalIF":1.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva ginecologica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S0026-4784.20.04691-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/11/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

Lymph node involvement is an important prognostic factor in early and advanced epithelial ovarian cancer (EOC). However, to date there is no reliable method of detecting lymph node involvement, apart from surgical staging. Thus, pelvic and paraaortic lymphadenectomy (LNE) are still part of standard surgery of early ovarian cancer. There is conflicting evidence about the therapeutic value of systematic LNE in early EOC. Thus, the developmemt of a method to predict nodal status accurately, without extensive LNE, is the subject of ongoing research. Sentinel lymphadenectomy (SLN) has become a standard procedure in oncological surgery. However, SLN is not yet an established and widely accepted procedure for EOC. This review aimed at summarizing available evidence on its feasibility and reliability in EOC. Overall, evidence of SLN in early EOC is still scarce. So far, only small series of patients with a variety of tracers and injection sites were published. From the available literature, the most promising technique seems to be injection into the infundibulopelvic, as well as the proper ovarian ligament. Indocyanine green seems to be an excellent tracer for successful SLN of ovarian tumors, which can be used during laparoscopic or robotic surgery. The detection rates and true positive rates of studies support further investigation of the technique. Results from prospective studies, e.g. the ongoing SELLY trial, are necesssary to implement SLN into the standard treatment of early EOC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
前哨淋巴结活检在卵巢癌中的作用。
淋巴结受累是早期和晚期上皮性卵巢癌(EOC)的重要预后因素。然而,迄今为止,除了手术分期外,没有可靠的方法检测淋巴结受累。因此,盆腔和主动脉旁淋巴结切除术(LNE)仍然是早期卵巢癌标准手术的一部分。关于系统性LNE在早期EOC中的治疗价值,有相互矛盾的证据。因此,开发一种方法来准确地预测节点状态,而不需要广泛的线,是正在进行的研究的主题。前哨淋巴结切除术(SLN)已成为肿瘤外科的标准手术。然而,SLN尚未成为EOC的既定和广泛接受的程序。本文旨在总结现有证据,证明其在EOC中的可行性和可靠性。总体而言,早期EOC的SLN证据仍然很少。到目前为止,只发表了小系列患者的各种示踪剂和注射部位。从现有的文献来看,最有希望的技术似乎是注射到骨盆底管,以及卵巢韧带。吲哚菁绿似乎是卵巢肿瘤SLN成功的良好示踪剂,可用于腹腔镜或机器人手术。研究的检出率和真阳性率为进一步研究该技术提供了依据。前瞻性研究的结果,例如正在进行的SELLY试验,对于将SLN纳入早期EOC的标准治疗是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Minerva ginecologica
Minerva ginecologica OBSTETRICS & GYNECOLOGY-
CiteScore
3.00
自引率
0.00%
发文量
0
期刊介绍: The journal Minerva Ginecologica publishes scientific papers on obstetrics and gynecology. Manuscripts may be submitted in the form of editorials, original articles, review articles, case reports, therapeutical notes, special articles and letters to the Editor. Manuscripts are expected to comply with the instructions to authors which conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Editors by the International Committee of Medical Journal Editors (www.icmje.org). Articles not conforming to international standards will not be considered for acceptance.
期刊最新文献
Minilaparoscopy in gynecology: applications, benefits and limitations. Re-birth in a Covid hospital: a point of view. Endometriosis-associated infertility: surgery or IVF? Cesarean delivery: an evidence-based review on of the technique. Approaching ovarian endometrioma with medical therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1